SPIRIT PRIME Clinical Trial

Completed · Phase 3

Conditions studied: Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis

In brief

To evaluate the safety and effectiveness of the XIENCE PRIME and XIENCE PRIME Long Lesion (LL) Everolimus Eluting Coronary Stent System (EECSS) in improving coronary luminal diameter in subjects with symptomatic heart disease due to a maximum of two de novo native coronary artery lesions, each in a different epicardial vessel.

Key facts

Study ID: NCT00916370
Run by: Abbott Medical Devices
People needed: 525
Starts: 2009-06-01
Expected to finish: 2014-02-01
Last updated by the study team: 2015-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subject must be at least 18 years of age.
Subject or a legally authorized representative must provide written informed consent prior to any study related procedure, per site requirements.
Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or a reversible change in the electrocardiogram (ECG) consistent with ischemia).
Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery.
Subject must agree to undergo all protocol-required follow-up procedures.
Subject must agree not to participate in any other clinical study for a period of one year following the index procedure.
Angiographic Inclusion Criteria
One or two de novo target lesions each in a different epicardial vessel.
If there are two target lesions, both lesions must satisfy the angiographic eligibility criteria for that registry.
o Multiple focal de novo lesions in a target vessel that can be covered by a single stent are allowed.
The target lesion(s) must be located in a major artery or branch with a visually estimated diameter stenosis of ≥ 50% and < 100% with a TIMI flow of ≥ 1.
Target lesion(s) must be located in a native coronary artery with reference vessel diameter (RVD) by visual estimation of:
≥ 2.25 mm and ≤ 4.25 mm for treatment by the core size XIENCE PRIME EECS
≥ 2.5 mm and ≤ 4.25 mm for treatment by the XIENCE PRIME LL EECS
Target lesion(s) must be located in a native coronary artery with length by visual estimation of:
≤ 22 mm for treatment by the core size XIENCE PRIME EECS
> 22 mm and ≤ 32 mm for treatment by the XIENCE PRIME LL EECS

You may not qualify if…

Subject has had a known diagnosis of acute myocardial infarction (AMI) preceding the index procedure (CK-MB ≥ 2 times upper limit of normal) and CK and CK-MB have not returned to within normal limits at the time of procedure.
The subject is currently experiencing clinical symptoms consistent with new onset AMI, such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes.
Subject has current unstable cardiac arrhythmias associated with hemodynamic instability.
Subject has a known left ventricular ejection fraction (LVEF) < 30% (LVEF may be obtained at the time of the index procedure if the value is unknown and if necessary).
Subject has received coronary brachytherapy in any epicardial vessel (target or non target).
Subject has received any organ transplant or is on a waiting list for any organ transplant.
Subject is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or within one year after the index procedure.
Subject is receiving or scheduled to receive planned radiotherapy to the chest/mediastinum.
Subject is receiving immunosuppressant therapy or has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.).
Subject is receiving chronic anticoagulation therapy (e.g., heparin, coumadin).
Subject will require Low Molecular Weight Heparin (LMWH) post-procedure.
Subject has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel/ticlopidine, everolimus, cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be adequately pre-medicated.
Elective surgery is planned within 12 months after the procedure that will require discontinuing either aspirin or clopidogrel.
Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a white blood cell (WBC) of < 3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis).
Subject has known renal insufficiency (examples being but not limited to estimated glomerular filtration rate (eGFR) < 60 ml/kg/m2, serum creatinine level ≥ 2.5 mg/dL, or on dialysis).
Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
Subject has had a cerebrovascular accident/stroke or transient ischemic neurological attack (TIA) within the past six months.
Subject has had a significant gastro-intestinal or significant urinary bleed within the past six months.
Subject has extensive peripheral vascular disease that precludes safe 6 French sheath insertion.
Subject has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year).
Subject is currently participating in another clinical study that has not yet completed its primary endpoint.
Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.
Angiographic Exclusion Criteria All angiographic exclusion criteria are based on visual estimation.
Target lesion located within an arterial or saphenous vein graft or distal to a diseased (vessel irregularity per angiogram and > 20% stenosed lesion) arterial or saphenous vein graft.
Target lesion involving a bifurcation with a side branch ≥ 2 mm in diameter and/or ostial lesion > 40% stenosed or side branch requiring protection guide wire, or side branch requiring dilatation.

Where it is running

Scottsdale Healthcare — Scottsdale, Arizona, United States
Mercy General Hospital — Sacramento, California, United States
Washington Hospital Center — Washington D.C., District of Columbia, United States
Morton Plant Hospital — Clearwater, Florida, United States
St. Vincents Medical Center — Jacksonville, Florida, United States
Orlando Regional Medical Center — Orlando, Florida, United States
Sacred Heart Hospital of Pensicola — Pensacola, Florida, United States
St. John's Hospital — Springfield, Illinois, United States
St. Vincent Heart Center of Indiana — Indianapolis, Indiana, United States
Iowa Heart Center P.C. — West Des Moines, Iowa, United States
University of Kansas Hospital — Kansas City, Kansas, United States
Willis Knighton Health System, Pierremont — Shreveport, Louisiana, United States
Union Memorial Hospital — Baltimore, Maryland, United States
Johns Hopkins Hospital — Baltimore, Maryland, United States
Peninsula Regional Medical Center — Salisbury, Maryland, United States
Washington Adventist Hospital — Takoma Park, Maryland, United States
Cape Cod Hospital — Hyannis, Massachusetts, United States
Bay Regional Medical Center — Bay City, Michigan, United States
Borgess Medical Center — Kalamazoo, Michigan, United States
Northern Michigan Hospital — Petoskey, Michigan, United States
Beaumont Hospital — Royal Oak, Michigan, United States
Abbott Northwestern Hospital — Minneapolis, Minnesota, United States
St. Luke's Hospital — Kansas City, Missouri, United States
Barnes Jewish Hospital — St Louis, Missouri, United States
Thomas Hospital — Fairhope, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.